University of Murcia research relating to P140
ImmuPharma PLC has noted early-stage research from the University of Murcia published in Autophagy regarding the P140 peptide's potential in glioblastoma, which the company has been aware of since 2024. These findings support ImmuPharma's broader scientific work on P140, although the company's primary focus remains on advancing P140 for autoimmune disease.
Select text to share a quote on X · sign in to keep highlights & notes in your IMM notes
ImmuPharma plc (LSE AIM: IMM), the specialist drug discovery and development company, notes the recent article published in the scientific journal Autophagy, which reports early-stage research conducted by the University of Murcia ("UoM") relating to the P140 peptide and its potential application in glioblastoma, an aggressive form of brain cancer.
ImmuPharma acknowledges the quality of the scientific work conducted by the UoM in this area and confirms that it has been aware of, and has followed, this research since 2024 and is in regular contact with the research team at UoM. These findings are supportive of ImmuPharma's broader scientific work on P140 and are consistent with the scientific rationale underlying the program.
P140 remains ImmuPharma's lead asset, and the Company's primary focus continues to be the advancement of P140 in autoimmune disease.
Further updates will be provided to the market when appropriate.
ImmuPharma PLC (www.immupharma.co.uk)
Tim McCarthy, Chief Executive Officer and Chairman
| Lisa Baderoon, Head of Investor Relations | + 44 (0) 7721 413496 |
| SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) Patrick Claridge, Bob Pountney SI Capital (Joint Broker) Nick Emerson | +44 (0) 203 368 8974 +44 (0) 203 650 3650 +44 (0) 1483 413500 |
About Reach announcements
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.